dr. burke on tazemetostat’s mechanism of action in ezh2-mutated follicular lymphoma
Published 4 years ago • 806 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
1:11
dr. maddocks on the role of tazemetostat in ezh2-mutant follicular lymphoma
-
1:25
dr. burke on risk stratification strategies in follicular lymphoma
-
0:54
dr. burke on research with tafasitamab in lymphoma
-
0:55
dr. burke on findings of goya study for diffuse large b-cell lymphoma
-
8:04
risk stratification in follicular lymphoma
-
1:17
dr. grossbard on the role of maintenance rituximab in follicular lymphoma
-
7:45
active monitoring for follicular lymphoma: louize's story
-
34:43
burkitt lymphoma
-
2:31
follicular lymphoma: diagnosis, prognosis, and treatment
-
3:23
the phase ii ezh2 inhibitor trial
-
9:37
lymphoma - dr. arturo loaiza bonilla
-
4:54
diagnosis and prognosis of follicular lymphoma
-
8:30
gallium trial: follicular lymphoma
-
1:47
john burke, md, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma
-
4:38
an in-depth look at treatment of follicular lymphoma
-
5:10
the burkitt lymphoma international prognostic index
-
3:02
mediola: olaparib and durvalumab for germline brca-mutated metastatic breast cancer
-
1:32
deciding on rituximab versus obinutuzumab in follicular lymphoma
-
2:49
overview of classical therapies for follicular lymphoma
-
1:50
dr. amengual on dual targeting with an hdac 6 inhibitor and bortezomib in lymphoma
-
13:46
understanding follicular lymphoma with sarah rutherford, md
-
1:31
dr. bello on biomarkers in follicular lymphoma